Abstract
A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have